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The present study characterized the homologous and heterologous immune response in type-I porcine
reproductive and respiratory syndrome virus (PRRSV) infection. Two experiments were conducted: in experiment 1,
eight pigs were inoculated with PRRSV strain 3262 and 84 days post-inoculation (dpi) they were challenged with
either strain 3262 or strain 3267 and followed for the next 14 days (98 dpi). In experiment 2, eight pigs were
inoculated with strain 3267 and challenged at 84 dpi as above. Clinical course, viremia, humoral response
(neutralizing and non-neutralizing antibodies, NA) and virus-specific IFN-γ responses (ELISPOT) were evaluated all
throughout the study. Serum levels of IL-1, IL-6, IL-8, TNF-α and TGF-β were determined (ELISA) after the second
challenge. In experiment 1 primo-inoculation with strain 3262 induced viremia of≤ 28 days, low titres of
homologous NA but strong IFN-γ responses. In contrast, strain 3267 induced longer viremias (up to 56 days), higher
NA titres (≤ 6 log2) and lower IFN-γ responses. Inoculation with 3267 produced higher serum IL-8 levels. After the
re-challenge at 84 dpi, pigs in experiment 1 developed mostly a one week viremia regardless of the strain used. In
experiment 2, neither the homologous nor the heterologous challenge resulted in detectable viremia although
PRRSV was present in tonsils of some animals. Homologous re-inoculation with 3267 produced elevated TGF-β
levels in serum for 7–14 days but this did not occur with the heterologous re-inoculation. In conclusion, inoculation
with different PRRSV strains result in different virological and immunological outcomes and in different degrees of
homologous and heterologous protection.Introduction
One of the main obstacles for the development of new
vaccines of greater efficacy against porcine reproductive
and respiratory syndrome virus (PRRSV) is the limited
understanding of the mechanisms involved in protection
[1-4]. Up to now, most studies have focused in the devel-
opment of neutralizing antibodies (NA) and to virus-spe-
cific interferon-γ secreting cells (IFN-γ-SC) as the main
correlates of protection [5–10] although the precise role* Correspondence: enric.mateu@uab.cat
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reproduction in any medium, provided the orof these elements is not well understood. Cross
neutralization experiments have shown that cross re-
activity between different PRRSV strains can be low and
even some PRRSV strains seem not to induce a neutral-
izing response at all [11,12]. Moreover, little is known
about cell mediated responses in heterologous challenge
models [8,10]. As a result, at present it is very difficult
–or impossible- to predict the panel of strains or the
characteristics of PRRSV isolates against which one pig
is effectively protected after immunization. As a matter
of fact, the common assumption is that immunity against
a homologous strain is sterilizing –or almost complete-
while immunity against other strains will depend, gener-
ically, on the degree of genetic/antigenic similarity be-
tween the immunizing and the infecting strains [1,13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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vaccine is scarcely predictive of protection [8,14].
It is worth to note that after a careful review of the
available scientific literature, there are very few charac-
terized models of homologous/heterologous challenge
considering simultaneously potential correlates of pro-
tection (NA and IFN-γ-SC), the development of clinical
signs and the virological outcome of the challenge
model. In the present study, we characterized the clinical
and virological course and the evolution of neutralizing
antibodies and interferon responses after inoculation
with two PRRSV strains previously reported to be differ-
ent [15,16]. We evaluated the neutralizing and IFN-γ-SC
responses against a heterologous strain after
immunization and we also tested the immunological
responses after the homologous and heterologous chal-
lenges of previously immunized pigs.Table 1 Experimental design
Groups 1st Challenge*
(0 pi)
2nd Challenge*
(84 pi)
Experiment
120 pigs
A strain
3262
Group A + A (n = 4)
Homologous challenge: strain 3262
14 pigs† Group A + B (n = 4)
Heterologous challenge: strain 3267
C1 Placebo Group C1 + B (n = 2)
6 pigs†† naïve controls: strain 3267
Experiment
211 pigs
B strain
3267
Group B + B (n = 4)
Homologous challenge: strain 3267
8 pigs Group B + A (n = 3**)
Heterologous challenge: strain 3262
C2 Placebo Group C2 + A (n = 3)
3 pigs naïve controls: strain 3262
* Inoculation was performed intranasally (2 mL; 1 mL/nostril) with a dosis of
5 × 105.0 TCID50/mL of the corresponding strain
** One pig died at 17 pi in the first inoculation.
† Six pigs were euthanized; three at 15 pi and three at 35 pi.
†† Four pigs were euthanized: two at 15 pi and two at +35 pi.Materials and Methods
Viruses
Two genotype I PRRSV strains designated as 3262 and
3267 were used in the present study. Strain 3262 was
isolated in 2005 from the lung of a pneumonic piglet
of a Spanish farm and strain 3267 was isolated in 2006
from serum of a boar of a Portuguese farm. Viral
stocks were produced from passage n = 3 in porcine al-
veolar macrophages (PAM). Viral titrations were per-
formed by inoculation in PAM and confirmation by
immunoperoxidase monolayer assay (IPMA) [17]. Viral
stocks were produced in an amount enough to allow
the use of a single batch of virus for all experiments
and assays reported below. Donor animals for PAM
were free of PRRSV, Aujeszky’s disease virus and other
major swine diseases including all internationally noti-
fiable diseases plus Mycoplasma hyopneumoniae and
swine influenza virus as shown by their serological sta-
tus. The animals had maternal antibodies against por-
cine circovirus type 2 (PCV2) but were free of virus as
determined by PCR using blood samples. PAM and
viral stocks used were shown to be free of PCV2,
Mycoplasma hyopneumoniae, hepatitis E virus and
Torque teno sus virus (TTSuV) by PCR as reported
before [18-21]. Strains used in the present study have
been characterized in vitro before with regards to their
impact on the phenotype of antigen presenting cells
and have been sequenced from ORF1a to ORF7 [15,16]
(Genbank accession numbers: JF276431 and
JF276435). Overall genetic similarity between strains
was 88.5 % [15]. Briefly, strain 3262 is known to induce
IL-10 and TNF-α release in dendritic cells while strain
3267 is unable to induce any of those cytokine in the
same system [16]. Strain 3262 also harbours a 74 aa
deletion in in nsp2 [15].Experimental design and animals
All experiments involving pigs were done under the ap-
proval of the Ethics Commission for Human and Animal
Experimentation of the Universitat Autònoma de
Barcelona (approval n° 665). Animals were kept in
approved experimental facilities and were subjected to
veterinary supervision for health and welfare. Handling
of pigs was done by veterinarians or trained personnel
allowed to do so under the Spanish and European Union
regulations. If necessary, animals were sedated for de-
creasing handling stress. Euthanasia was performed by
pentobarbital overdose according to European Union
and Spanish regulations.
The study was developed in two consecutive experi-
ments (Table 1) carried out in biosafety level 3 facilities
of CReSA one immediately after the other. Experiments
were carried out using pigs of the same origin (same
farm, same genetic background, etc.) and were housed
under the same controlled environmental conditions.
Source farm was historically free of PRRSV and pigs were
re-confirmed to be free of PRRSV by ELISA (Herdcheck
2XR, Idexx Laboratories) and RT-PCR [22] and free of
PCV2 by PCR [19]. In both experiments, upon arrival at
the experimental facilities, pigs were ear-tagged, weighed,
bled and randomly distributed (random numbers) in two
pens; then, piglets were left to acclimatize for one week.
Inoculations were always done by the intranasal route
using 2 mL (1 mL/nostril) of the appropriate PRRSV
strain at a dose of 5 × 105.0 TCID50/mL. Control animals
received 2 mL of sterile RPMI by the intranasal route
when necessary.
Also, at the start and at the end of the experiment
serum samples were examined by ELISA for antibodies
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and hepatitis E virus [23]. Presence of TTSuV was
assessed by PCR as reported [21]. Other examined
pathogens were Aujeszky’s disease virus (Herdcheck PRV
gE, Idexx Laboratories, Barcelona, Spain), Mycoplasma
hyopneumoniae (Ideia Mycoplasma Hyopneumoniae EIA
KIT, Oxoid, Cambridge, UK) and swine influenza virus
(Civtest suis influenza, Hipra Laboratories, Amer, Spain).
All animals were seronegative to those pathogens when
the experiments ended.
In experiment 1, 20 three-week-old piglets were
divided in two groups: A (n= 14) and C1 (n= 6). Group
A was inoculated with strain 3262 and group C1 received
RPMI as a placebo. At 15 dpi, three piglets of group A
and two animals of group C1 were euthanized and sub-
jected to a complete necropsy. On day 35 post-inocula-
tion (pi), three further A piglets and two control animals
(C1) were euthanized and subjected to necropsy.
Remaining animals (eight in group A and two in C1)
were followed up until day 84 pi. At that time, four A
piglets were randomly selected (random numbers), sepa-
rated in a different isolation box and inoculated with
strain 3262 (group A+A corresponding to the homolo-
gous challenge (HoC) for experiment 1). The other four A
pigs were inoculated with strain 3267 (group A+B;
namely a heterologous challenge (HeC) for experiment 1).
C1 pigs were challenged with PRRSV strain 3267 (from
now on C1+B). All animals were monitored for the fol-
lowing two weeks and then were euthanized and subjected
to necropsy (day 98 pi, 14 days post-second challenge).
In experiment 2, 11 three-week-old animals were used.
Initially two groups were formed: B (n= 8) and C2
(n= 3). B animals were inoculated with strain 3267 and
animals in C2 received RPMI. In this case sequential
necropsies at days 15 and 35 pi were not done. Eighty
four days later (day 84 pi), four B pigs were inoculated
again with strain 3267 (B +B group, HoC for experiment
2) and 3 piglets (one piglet died at day 17 pi after the ini-
tial challenge) received strain 3262 (B +A, HeC for ex-
periment 2). C2 animals were also challenged then with
PRRSV strain 3262. Animals were monitored for the fol-
lowing two weeks as above.Clinical follow-up and sample taking
In both experiments, animals were clinically examined
on arrival and then were monitored for the development
of clinical signs including fever: 18 days in experiment 1
or for 36 days in experiment 2. This difference in the
periods for which rectal temperatures were recorded was
attributable to the fact that feverish pigs were still
observed at 14 pi in experiment 2. Weights were
recorded weekly from day 0 to 42 pi. Blood samples were
taken (siliconized and heparinized tubes) weekly.Pathology
At necropsy, samples were systematically taken from
lungs (portions of all lobes of the right lung plus the
accessory lobe), submandibular, tracheobronchial, mes-
enteric and inguinal superficial lymph nodes, tonsils, thy-
mus and spleen. If relevant gross lesions were found
besides those organs, additional ad hoc samples were
taken. All organs were sampled in duplicate; one sample
was fixed in 10 % neutral buffered formalin and embed-
ded in paraffin and the other was frozen at −80°C until
needed for further analysis. Tissues were examined histo-
pathologically (haematoxylin/eosin staining) for evaluat-
ing the nature and severity of lesions. In order to avoid
biases, this examination was done in a blinded fashion
by three pathologists. For interstitial pneumonia, a 4
grade score was used: 0 (no lesion), 1 (mild), 2
(moderate) and 3 (severe). Similar grading was used for
the evaluation of lymphoid hyperplasia (white pulp
hyperplasia in spleen and follicular hyperplasia in lymph
nodes and tonsil). For thymus, the ratio cortex to me-
dulla was calculated and the presence of tingible body
macrophages was evaluated in thymus (0 to 4 scale,
0 = none; 1 = low, 2 =moderate, 3 = high, 4 = very high).
Also, lymphoid tissues were analysed by in situ
hybridization (ISH) to assess presence of PCV2 as previ-
ously described [25]. In case that in the course of nec-
ropsies gross lesions indicative of bacterial infections
were found, appropriate microbiological cultures were
performed.
Virological analysis
The evolution of viremia was initially assessed by viral
isolation in PAM and by nested RT-PCR (nRT-PCR). For
this, blood samples were serially diluted from 100 to 10-4
and inoculated in PAM cultures (50 μL in quadrupli-
cates). Isolation was verified at day 3 pi in PAM by
means of IPMA as reported above. For each animal,
serum samples were re-tested for the presence of PRRSV
by nRT-PCR [6] starting in the last sample (in chrono-
logical order) producing a positive viral isolation. For for-
malin fixed tissues, PRRSV presence was determined
initially by means of an immunohistochemical technique
(IHC) [25]. For lungs, tonsils and spleen, samples produ-
cing negative IHC were then re-tested using the same
nRT-PCR as above, adapting RNA extraction procedure
to frozen tissues.
In order to examine if viremia at late times after the
different challenges corresponded to the predominance
of neutralization escape mutants, RNA was extracted
from selected samples and analysed for ORF4 and ORF5
specific sequences according to previously reported
methods [15]. In order to assess if virus present in tis-
sues after the second challenge corresponded to persist-
ent infection or not, sequencing for ORF5 was
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HeC pigs.
Humoral response
Serum samples were analysed by means of a commercial
ELISA (HerdCHeck 2XR, Idexx Laboratories). Results
were reported as a ratio (S/P) of optical densities be-
tween the results of a given sample and the positive con-
trol included in the kit (cut-off: S/P ≥ 0.4). All serum
samples were tested the same day and in the same batch
of plates.
Also, levels of NA were determined. Since the used
PRRSV strains could not be adapted to grow in MARC-
145 cells at low passages (n ≤ 4), viral neutralization tests
(VNT) were done in PAMs. In order to test the cross-re-
activity of antibodies against strains 3262 or 3267, VNT
were performed in parallel with each viral strain. Briefly,
sera were diluted (in duplicate) in a serial dilution (log2)
from 1/2 to 1/256, inactivated at 56°C 30 min and incu-
bated overnight 1:1 vol/vol at 4°C with one or the other
of the abovementioned strains (2000 TCID50/mL). PAMs
were cultured in 96 wells plates (50 000/well) with the
virus-serum mixture. After 72 h of incubation, PAMs
were fixed in absolute ethanol at −20°C until needed.
The reaction was revealed by means of a peroxidase con-
jugate using a non-neutralizing monoclonal antibody
against ORF5 (3AH9; Ingenasa, Madrid, Spain) and in-
soluble TMB (TMB/h; Milipore, Billerica, USA) as a
chromogen. In order to have an assessment of the accur-
acy of the measurement, testing was done twice for days
42 pi, 84 pi and 98 pi (14 post second challenges). In
addition, to test if negative neutralization results at 72 h
post-inoculation of PAM could be due to selection and
growth of a neutralization escape mutant variants or
quasispecies present in the original virus stock, a panel
of selected sera yielding negative results in the VNT were
used in a second VNT that was performed as above but
revealed after 12 h of incubation of PAM with the virus/
serum mixture in order to avoid propagation of the
hypothetical neutralization escape mutants.
IFN-γ ELISPOT
Evaluation of the cell-mediated immune response (CMI)
was done by the IFN-γ ELISPOT using peripheral blood
mononuclear cells (PBMC) [6,26] at days 0, 21, 42, 63,
70, 77 and 84 pi plus on days 91 and 98 (7 and 14 post
second challenges, respectively). In order to evaluate the
in vitro homologous and heterologous responses in the
IFN-γ ELISPOT, PBMC were stimulated in parallel (500
000 PBMC/well, 3 wells per pig and stimulus) with
strains 3262 and 3267 at multiplicity of infection (m.o.i.)
of 0.01. Unstimulated cells and phytohemagglutinin-sti-
mulated controls (10 μg/mL) were also included.
PRRSV-specific corrected frequencies of IFN-γ-SC werecalculated by subtracting counts of spots in unstimulated
wells from counts in virus-stimulated wells. Frequencies
of IFN-γ-SC were expressed as responding cells in 106
PBMC.
Cytokine ELISAs
In both experiments serum samples were taken at days
0, 1, 2, 3, 7 and 14 post second challenges (first challenge
for control groups C1 and C2) and tested by ELISA for
determining serum levels of TNF-α, IL-1, IL-6, IL-8, IL-
10 and TGF-β. ELISAs were performed using commer-
cial pairs of monoclonal antibodies according to manu-
facturer’s instructions: TNF-α, IL-1, IL-6 and IL-8
(Porcine TNF-α, IL-1, IL-6 and IL-8 DuoSet, respectively;
R&D Systems, Minneapolis, USA) and IL-10 and TGF-β
(IL-10 Swine Antibody pair and TGF-β1 Multispecies
ELISA Kit; Invitrogen). The cut-off of each ELISA was
calculated to be equal to the mean optical density (OD)
of negative controls plus three standard deviations (cut-
off = 32 pg/mL for IL-6, IL-10, TNF-α, TGF-β1; cut-off =
62 pg/mL for IL-1 and IL-8). For a given sample, the
OD was then transformed to concentration by applying a
linear regression formula calculated from the results of
the standards provided in each kit. In order to account
for the pre-2nd challenge levels of a given cytokine,
values (pg/mL) obtained with samples of day 0 (84 pi)
were subtracted to the values obtained at days 1, 2, 3, 7
or 14 producing thus a corrected value (Corrected value
for cytokine X=Concentration of cytokine X day n - Con-
centration of cytokine X day 0).
Statistical analysis
Statistics were performed using StatsDirect v2.7.7. Krus-
kal-Wallis test (Conover-Inman method for multiple
comparisons) was used for comparisons of means be-
tween groups and the Log Rank & Wilcoxon test was
used for comparing the duration of viremias. Compari-
son of the proportion of infected tissues was determined
by the χ2 test (Fisher’s exact test). EpiCalc 2000 was used
for calculation of confidence intervals of proportions.
Results
Clinical follow-up and weight gains
Figure 1 shows the evolution of body temperatures and
weight gains in experiments 1 and 2. In both experi-
ments inoculation of PRRSV induced moderate fever, up
to 40.4°C, during at least the first 14 days pi. In the case
of experiment 2, fever was more prolonged and body
temperatures of inoculated animals were significantly
higher (p< 0.05) compared to controls until day 22 pi.
In experiment 1, respiratory signs were absent or very
mild while in experiment 2, dullness and respiratory
signs were slightly more evident including occasional
coughing and laboured breath. In the second experiment
d1-d14*
d1-d16 and d19-d22*
*
Experiment 1 Experiment 1
a
a
a
a
a
a
b
c
2nd
challenge
2nd
challenge
n.s.
n.s.
Average weekly weight gain (Kg)a
b
c
d
Figure 1 Rectal temperature and body weight gains after inoculation with PRRSV. Evolution of average rectal temperatures and body
weight gains in experiments 1 (figure a-c) and 2 (b-d). In experiment 1, animals received initially (day 0 pi) PRRSV strain 3262 (A; black crosses,
light grey bars) or were mock-inoculated (Control; empty circles, empty bars). At day +84 pi, four pigs were challenge with strain 3262 again
(A + A; black triangles, black bars) or received a heterologous challenge with strain 3267 (A+ B; grey rhombus or dark grey bars). Naïve pigs were
challenged with strain 3267 (C1 + B; empty squares or diagonal line bars). In experiment 2, pigs were initially inoculated with strain 3267 (B) and
later challenged with 3267 (B + B) or 3262 (B + A). Controls were included (Control and C2+A). Significant (p< 0.05) differences in body
temperatures are marked with an asterisk. For weight gains (right side of the figure), bars with a letter above show significant (p< 0.05)
differences.
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ous to fibrous pleuritis, catarrhal bronchopneumonia
and interstitial pneumonia, suggesting a bacterial compli-
cation that could not be confirmed in the microbio-
logical analysis. Regarding weight gains, in Experiment 1
inoculated animals showed decreased weight gains
(p< 0.05) compared to controls until day 21 pi and in
experiment 2 differences were noticeable until 42 pi. For
the first 42 days pi, weight gains of control pigs were
33.3 Kg in experiment 1 and 31.3 Kg in experiment 2,
while weight gains for virus inoculated animals in the
same period were 30.5 Kg in experiment 1 and 16.3 Kg
in experiment 2 (p< 0.05).After the second challenge, clinical signs were absent
in both experiments except in control animals (C1 and
C2) that were immunologically naive and showed fever
occasionally. After the second challenge weight gains
were significantly different among groups (p< 0.05) and
always animals subjected to a HoC had better gains than
animals subjected to HeC or than naïve pigs inoculated
for the first time.
Pathology
In experiment 1, necropsies performed at day 15 pi
showed that inoculated animals developed gross intersti-
tial pneumonia that microscopically ranged from slight
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those observed in lungs. At that time (15 pi) PRRSV was
detected by IHC in lungs of all inoculated animals. Unin-
oculated controls did not develop gross or microscopic
lesions and were free of PRRSV by IHC. At day 35 pi,
inoculated pigs did not show macroscopic or micro-
scopic signs of interstitial pneumonia and were negative
to PRRSV by IHC.
Regarding the development of lesions after the second
challenge in experiment 1 -that took place at day 84 pi-
none of the pigs showed macroscopic evidence of inter-
stitial pneumonia, except for one in A+B group. Micro-
scopically (Table 2), both the HoC and the HeC groups
showed similar lesions of interstitial pneumonia with
scores ranging from slight to severe depending on the
lung lobe examined. Control animals infected with strain
3267 for the first time (C1 +B) had similar lung lesions
than the HoC or the HeC group. In experiment 2, nec-
ropsies performed two weeks after the second challenge
showed that only one pig (B +A group) had signs of
gross interstitial pneumonia.
No differences were observed between groups regard-
ing lymphoid hyperplasia in spleen, tonsils or lymph
nodes in none of the experiments. However, density of
tingible body macrophages was apparently higher in the
B +A group compared to the others (not shown).Virological analysis
Results of the evolution of viremia are shown in Tables 3
and 4. Inoculation of naive pigs with strain 3262 (experi-
ment 1) resulted in viremia (nRT-PCR) by day 7 pi in all
animals. The proportion of viremic pigs declined after-
ward to 11/14 by day 14 pi (78.6 %; CI95%: 48.8-94.3 %),
4/11 at 21 pi (36.4 %; CI95%: 12.4-68.4 %) and 1/11 at 28
pi (9.1 %; CI95%: 0.5-42.9 %). By day 35 pi all inoculatedTable 2 Results of the histopathological examination of
lungs
Experiment Group Interstitial pneumonia*
1 C1+B 5.0 ± 2.8a
A+A 6.5 ± 3.8a
A+B 6.8 ± 1.3a
2 C2+A 8.7 ± 2.3b†
B+B 6.5 ± 2.6a
B+A 5.3 ± 0.6a
Different superscript letters indicate significant differences (p< 0.05) between
the groups in a given experiment according to the Kruskal-Wallis test
(Conover-Inman test for multiple comparisons). No significant differences were
seen for the double challenged groups between experiment 1 and 2.
* Microscopic interstitial pneumonia was evaluated in 4 portion of lung
corresponding to the apical, cardiac, diaphragmatic and intermediate lobes,
scored in a 4-grade scale (0 = absent to 3 = severe). The values shown
correspond to the average of the summatory of scores for each pig in a given
group and the standard deviation of the summatories. With this calculation,
maximum possible average is 12.
† In the case of group C2 +A; p=0.06.animals had become negative in blood and tissues (nRT-
PCR and IHC). Viral load in serum peaked at 7 pi (aver-
age viral titre of 103.1 TCID50/mL) and declined later on.
After the second challenge at day 84 pi, all animals, re-
gardless of the previous status of immunization or the
strain used for this second challenge, became infected
again as shown by results of sera by nRT-PCR (Table 4);
however, viral isolation from blood was only achieved for
PRRSV-naïve pigs. Examination of tissues by IHC and
nRT-PCR (Table 5) revealed that 14 days after the sec-
ond inoculation, PRRSV could be detected in lungs of 2/
4 pigs in both the HoC and HeC groups. In contrast, a
trend for a significantly higher presence of virus in ton-
sils was observed in the HeC compared to the HoC
(p= 0.07).
In experiment 2, all animals were viremic (nRT-PCR)
for the first 35 days pi and by day 56 pi 3/7 pigs were
still positive (42.9 %; CI95%: 11.8-79.8 %). Regarding viral
isolation and titration, viremia peaked at day 7 pi with
an average viral load in serum of 103.7 TCID50/mL and
viral load remained above 103.0 TCID50/mL for 21 days
pi. From day 14 pi onwards, viral loads were higher in
animals infected with strain 3267 compared to animals
infected with strain 3262 in experiment 1 (p< 0.05) and
duration of viremia was also statistically longer
(p< 0.05). To test if the longer viremia seen for strain
3267 was attributable to the generation and expansion of
neutralization escape mutants in the course of infection,
viral isolates of day 49 pi were sequenced for the ORF4
and ORF5. Results of sequencing showed that the NE in
GP4 changed during the course of the infection and that
GP5 gained one potential glycosylation at N37 (DSS
!NSS).
After the second challenge of day 84 pi only PRRSV-
naïve pigs developed a detectable viremia that lasted
until the end of the experiment (Table 4). Examination
of tissues indicated however that at least two animals in
the HoC group and one animal in the HeC group had
become infected as demonstrated by the presence of the
virus in tonsils (Table 5). Sequencing demonstrated that
the virus found in the HeC experiments always corre-
sponded to the heterologous virus and was not a
remnant of the initial inoculation.Humoral response
After inoculation with either one or the other PRRSV
strain, pigs rapidly developed antibodies detectable in
ELISA although S/P ratios were different among groups.
Thus, for the first 84 days pi (except at day 35 pi) S/P
ratios were higher (p< 0.05) in animals inoculated with
3267 -experiment 2- than in animals inoculated with
3262- experiment 1- (Figure 2a). After the second chal-
lenge (day 84 pi), re-inoculated animals became similar
Table 3 Detection of virus in sera by isolation in porcine alveolar macrophages and by nested RT-PCR after first
challenge with PRRSV
Days post 1st inoculation (pi)
Experiment Assay 7 14 21 28 35 42 49 56 63 70 77 84
1
Viral isolation
(titre)
14/14 11/14† 4/11 1/11 0/11 0/8 0/8 0/8 0/8 0/8 0/8 0/8
3.1 ± 0.6 2.9 ± 0.5 2.3 ± 0.2 2.3 ± 0.0 - - - - - - - -
nRT-PCR 14/14 11/14 4/11 1/11 0/11 0/8 0/8 0/8 0/8 0/8 0/8 0/8
2
Viral isolation
(titre)
8/8 8/8 7/7††* 7/7* 7/7* 3/7* 3/7* 1/7* 0/7 0/7 0/7 0/7
3.7 ± 0.3 3.4 ± 0.5 3.2 ± 0.8 2.6 ± 0.5 2.2 ± 0.2 2.0 ± 0.3 2.0 ± 0.3 1.8 ± 0.0 - - - -
nRT-PCR N.D. N.D. N.D. N.D. N.D. 4/7 4/7 3/7 0/7 0/7 0/7 0/7
Results of viral titration of sera in porcine alveolar macrophages (PAM) using the immunoperoxidase monolayer assay are expressed as number of positive pigs
over the number of pigs in the group and as the mean ± standard deviation (log10) of titres (TCID50/mL) of positive pigs. *p< 0.05 for the comparison of infected
groups between experiment 1 (strain 3262) and 2 (strain 3267). For the nRT-PCR results only show the number of positive pigs in the second round of the PCR.
Results of control (uninoculated) pigs are not shown because they were always negative from day 0 to 84 post-inoculation.
† Three pigs were euthanized at day 15 pi and three pigs more were killed at day 35 pi.
†† One pig died at day 17 pi.
N.D. Not done
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(Figures 2b and 2c).
Development of NA against the homologous and the
heterologous strains was examined in VNT using PAM
(Table 6). In experiment 1, after the first inoculation
none of the pigs developed NA against the inoculation
strain 3262 (homologous VNT). After challenge at day
84 pi, serum of pigs re-inoculated with either 3262 or
3267 did not show neutralizing activity against strain
3262. In contrast, in experiment 2 (inoculation with
strain 3267) NA against the homologous strain wereTable 4 Detection of virus in sera by isolation in porcine
alveolar macrophages and by nested RT-PCR after the
second challenge with PRRSV
Days post-2nd challenge
Positive/total
Viral titre ± standard deviation
Experiment Group Assay +7 (91 pi) +14 (98 pi)
1
C1 + B Viral isolation 2/2 2/2
3.2 ± 0.6 2.0 ± 0.0
nRT-PCR 2/2 2/2
A + A Viral isolation 0/4 0/4
nRT-PCR 4/4 1/4
A + B Viral isolation 0/4 0/4
nRT-PCR 4/4 0/4
2
C2 + A Viral isolation 3/3 2/3
3.4 ± 0.9 2.2 ± 0.1
nRT-PCR 3/3 3/3
B + B Viral isolation 0/4 0/4
nRT-PCR 0/4* 0/4
B + A Viral isolation 0/4 0/4
nRT-PCR 0/4* 0/4
*Asterisks indicate statistical differences in the proportion of pigs found to be
positive by RT-PCR in comparable groups of experiments 1 and 2 (i.e.
homologous A + A versus homologous B + B).demonstrated in some pigs already by day 21 pi and by
day 42 all inoculated pigs were positive for NA. At day
84 pi, titres of homologous (3267) NA ranged from 3
log2 to 6 log2. After the second challenge (day 84 pi),
most animals showed an increase of the homologous
(3267) VNT titres by 1–2 log2. Naïve pigs inoculated
with 3267 for the first time at 4 months of age in experi-
ment 1 already showed NA titres in the range of 2–3
log2 against that strain 14 days after the inoculation (day
98).
When cross-neutralization tests were performed, the
picture was different. Thus, in experiment 1 by day 84 pi
sera of 6/8 animals (75 %; CI95%: 35.6-95.6 %) showed
neutralizing activity against 3267 (heterologous in this
case) but with low titres (1–3 log2). After the second
challenge, a boost in the VNT titres against 3267 (3–6Table 5 Distribution of PRRSV in tissues after the
homologous or heterologous challenge by nested RT-PCR
or immunohistochemistry (IHC)
Nº positives/Nº examined
Experiment Group Assay Lung Tonsil Spleen
1
C1 + B nRT-PCR 0/2 2/2 1/2
IHC 0/2 1/2 0/2
A + A nRT-PCR 2/4 1/4 1/4
IHC 0/4 1/4 1/4
A + B nRT-PCR 2/4 4/4* 3/4
IHC 0/4 0/4 1/4
2
C2 + A nRT-PCR 1/3 1/3 0/3
IHC 0/3 0/3 0/3
B + B nRT-PCR 0/4 2/4 0/4
IHC 0/4 0/4 0/4
B + A nRT-PCR 0/3 1/3 0/3
IHC 0/3 1/3 0/3
*p = 0.07
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Figure 2 Evolution of the humoral response (ELISA) against PRRSV in experiments 1 and 2. 2a. Average sample to positive (S/P) ratios of
optical densities from day +15 to +84 post-inoculation. Empty bars correspond to pigs in experiment 1 (strain 3262: A); grey bars correspond to
pigs in experiment 2 (strain 3267: B). Lines show results of control (un-inoculated pigs) in both experiments.2b. Serological evolution (S/P ratios) of
pigs in experiment 1 after the second challenge (84 pi). Empty bars correspond to the homologous challenge (group A+A), grey bars to the
heterologous challenge (A + B) and black bars depict results of naïve pigs inoculated for the first time with strain 3267 (C1+ B)2c. Serological
evolution (S/P ratios) of pigs in experiment 2 after the second challenge (84 pi). Empty bars: (B + B); grey bars: B + A; black bars: naïve pigs
inoculated for the first time with strain 3262 (C2+ A).In all cases, different superscript letters indicated statistically significant differences (p< 0.05)
as determined in the Kruskal-Wallis test; n.s. = non-significant.
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http://www.veterinaryresearch.org/content/43/1/30log2) was seen regardless of the strain used for that sec-
ond challenge. In experiment 2, sera of pigs inoculated
with 3267 showed a weak neutralizing activity against
3262 (heterologous) by day 84 pi (1–4 log2). After the sec-
ond challenge, heterologous titres against 3262 did not
substantially increase except for one pig (receiving 3267
again).
Evolution of the IFN-γ ELISPOT after the initial challenge
For each of the experiments, the IFN-γ ELISPOT was per-
formed using in parallel each of the strains included in the
study in order to examine the homologous and heterol-
ogous response (Figures 3a and b). In experiment 1, inocu-
lation with strain 3262, the use of the same 3262 strain in
the ELISPOT revealed a peak of virus-specific IFN-γsecreting cells (SC) by day 21 pi; thereafter frequencies
decreased to a low by day 63 pi. Using the strain 3267 as
stimulus (heterologous stimulation in this case), the trend
was similar but with significantly (p< 0.05) lower frequen-
cies of responding cells in all examined days.
In experiment 2, inoculation with strain 3267, the ELI-
SPOT using the strain 3267 produced a similar temporal
trend with the lowest frequencies at days 42 and 63 pi.
In this case, the use of strain 3262 (heterologous stimula-
tion in ELISPOT), resulted in much higher frequencies
(p< 0.05) for the first 70 days pi and almost significant
differences (p= 0.06) were still determined by day 77 pi.
When equivalent series of IFN-γ ELISPOT results were
compared between experiments; namely, homologous
stimulation in experiment 1 versus homologous stimulation
Table 6 Viral neutralization test results using PRRSV strains 3262 and 3267
Nº of responding pigs; mean titre (log2) and standard deviationRange of titres (log2) for positive pigs
Strain used in the viral neutralization test
3262 3267
Days post-inoculation Days post-inoculation
Challenge group† 21 42 84 98 21 42 84 98
A + A 0/4 0/4 0/4 0/4 0/4 3/4* 4/4* 4/4*
(3262+3262) - - - - - 1.7 ± 0.6a 2.0 ± 0.8a 4.25 ± 1.0b
(1–2) (1–3) (3–5)
A + B 0/4 0/4 0/4 0/4 0/4 2/4 2/4 4/4*
(3262+3267) - - - - - 1.0 ± 0.0a 2.0 ± 0.0a 5.3 ± 0.5b
(1–1) (2–2) (5–6)
C1 + B 0/2 0/2 0/2 0/2 0/2 0/2 0/2 2/2*
(C+3267) - - - - - - - 2.5 ± 0.5
(2–3)
B + B 0/4 2/4 4/4‡ 4/4‡ 4/4‡ 4/4 4/4 4/4
(3267+3267) 0/4 1.0 ± 0.0 2.2 ± 1.5 2.8 ± 1.7 2.0 ± 0.8a 2.5 ± 1.0a 4.8 ± 1.0b 6.0 ± 0.8b¶
- (1–1) (1–4) (1–5) (1–3) (2–4) (4–6) (5–7)
B + A 0/3 0/3 3/3‡ 3/3‡ 1/3 3/3 3/3 3/3
(3267+3262) 2.0 ± 1.0 1.3 ± 0.6 1.0 ± 0.0 3.0 ± 1.0a 4.0 ± 1.0a 5.3 ± 0.6b
- - (1–3) (1–2) (1–1) (2–4) (3–5) (5–6)
C2 + A 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
(C+3262) - - - - - - - -
† Chronological sequence of strains used for inoculation is shown in parentheses.
* The asterisk show statistical differences (p< 0.05) for the proportion of responding pigs using one or the other PRRSV strain.
Superscript letters indicate statistical differences (p< 0.05; ¶ p = 0.08) in the average titres between different days using a given strain.
‡ The symbol indicates statistically significant differences for the proportion of responding pigs for similar groups between experiments (i.e. homologous A + A vs.
homologous B + B) using the same strain.
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ment 1 versus heterologous stimulation in experiment 2,
differences were also seen. Thus, inoculation with 3262 pro-
duced higher frequencies of IFN-γ cells (p< 0.05) for days
21, 42 and 77 pi compared to the inoculation with 3267
(104 ±73 vs. 38±30; 54±24 vs. 9 ±9 and 106±69 vs.
34±25, respectively). Comparing results of heterologous
stimulation in ELISPOT, the use of strain 3262 resulted in
higher responses (p< 0.05) at days 21, 42, 63 and 70 pi
(181±102 vs. 29±19; 68±37 vs. 14±12; 91±22 vs. 2 ±3
and 101±34 vs. 22±20).
Evolution of the IFN-γ ELISPOT after the second challenge
Figures 4a and b summarize this part of the experi-
ment. After the challenge of day 84 pi, the behaviour
of the IFN-γ-SC response varied depending on the ex-
periment. Thus, for experiment 1 (initial immunization
against strain 3262), re-inoculation of PRRSV resulted
in a significant boost of the IFN-γ ELISPOT responses
both in the HoC and in the HeC groups by day 91 ex-
cept for animals that had reached frequencies of IFN-γ
SC ≥ 100 before the challenge. In this case again, use
of strain 3267 in the ELISPOT resulted in lowerfrequencies regardless of the strain used for challenge.
In experiment 2, re-inoculation of PRRSV did not pro-
duce a clear pattern.
Cytokine (IL-1, IL-6, IL-8, TNF-α, IL-10, and TGF-β) ELISAs
Cytokine levels in serum were examined only after the sec-
ond challenge of each experiment and in naïve control
pigs. Regarding IL-1, all samples were below the assay de-
tection limit in both experiments. For IL-6, in experiment
1 two animals in each group (A+A and A+B) had detect-
able levels of this cytokine from day 1 to 7 post-challenge;
naïve pigs inoculated for the first time produced negative
results. In contrast, all samples yielded negative results for
IL-6 in experiment 2.
For IL-8 (Table 7), differences were noticed among
groups and treatments. In experiment 1, naïve pigs inocu-
lated for the first time at day 84 with strain 3267 were
positive for IL-8 (corrected concentration) at days 1, 2, 3
and 7 post-challenge. In contrast, in the HeC model IL-8
was only detected at days 1 and 2. In the HoC, at least one
animal produced a positive result every examined day but
no constant pattern was seen. In experiment 2, the picture
was the opposite to that of experiment 1. Naïve animals
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Figure 3 PRRSV-specific cell-mediated immune response as determined by the IFN-γ ELISPOT, days 21 to 84 pi. Peripheral blood
mononuclear cells (PBMC) were stimulated with either of the PRRSV strains (3262 or 3267) used in the study. Results are shown (columns) as
average frequencies of virus-specific IFN-γ secreting cells per million of PBMC obtained in the ELISPOT with the corresponding standard deviations
(bars). For each experiment the results of ELISPOT are shown in two series: darker shadowed columns indicate results obtained after in vitro
stimulation with the same PRRSV strain with which had been immunized initially (homologous) while lighter coloured bars show the results of
in vitro stimulation with other PRRSV isolate used in the present study (heterologous). Asterisks indicate significant differences between results
obtained in the homologous and the heterologous ELISPOT for each experiment (*p< 0.05; **p< 0.01; † p= 0.07) at a given time point. Letters
indicate significant differences (p< 0.05) among different time points in a given series. For each time point and series, the number of responding
pigs over the total number of examined pigs is shown. 3A= Experiment 1 (inoculation with strain 3262); 3B = Experiment 2 (inoculation with strain
3267). dpi = days post-inoculation.
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http://www.veterinaryresearch.org/content/43/1/30inoculated for the very first time with 3262 produced IL-8
results below the assay detection limit at all points. In con-
trast, at least one animal had detectable IL-8 levels at any
given time after the HoC or HeC. For TNF-α, no signifi-
cant differences were noticed and for IL-10, in both
experiments positive results were sporadic.
For TGF-β (Table 8), a different outcome was seen
depending on the experiment and group. Thus, inexperiment 1, naïve pigs inoculated with 3267 were
sporadically positive similarly to what occurred in
naïve pigs inoculated with 3262 in experiment 2. In
experiment 1, both in the HoC and in the HeC, re-in-
oculation with PRRSV induced increased levels of
TGF-β that peaked at day 7 or 14 post challenge. In
experiment 2, differences were seen depending on the
strain used for re-inoculation. Thus, while in the HoC
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Figure 4 Individual responses in the IFN-γ ELISPOT after second challenge that took place at day 84 pi. Bars depict individual frequencies
of virus-specific IFN-γ secreting cells after the homologous and heterologous challenge for this experiment. ELISPOTs were performed with both
strains used in the present study.
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Table 7 Serum levels of IL-8 after challenge with PRRSV
at 84 days after the initial inoculation
Corrected† IL-8 levels in serum (pg/mL)
N° responding pigs; Average± standard deviation
Experiment 1
Group
Days post-challenge
1* 2* 3 7} 14
C1+B 2/2a
270 ± 108
2/2a
424 ± 255
2/2a
440 ± 434
2/2a
470 ± 606
1/2
711 ±N.A.
A+A 0/4
N.A.
1/4
440 ±N.A.
2/4
272 ± 363
1/4
822 ±N.A.
1/4
124 ±N.A.
A+B 2/4
644 ± 479
3/4
194 ± 98
0/4
N.A.
0/4
N.A.
0/4
N.A.
Experiment 2
Group
Days post-challenge
1 2 3 7 14}
C2+A 0/3b
N.A.
0/3b
N.A.
0/3b
N.A.
0/3b
N.A.
0/3
N.A.
B+B 3/4
249 ± 192
1/4
526 ±N.A.
2/4
212 ± 211
2/4
262 ± 247
3/4
297 ± 273
B+A 2/3
38 ± 2
1/3
667 ±N.A.
2/3
1088 ± 407
1/3
577 ±N.A
3/3
291 ± 117
† In order to account the pre-2nd challenge levels of a given cytokine, values
(pg/mL) obtained with samples of day 0 (84 pi) (C1 + B:653 ± 66;
A + A:796 ± 306; A + B:1062 ± 157; C2 +A:503 ± 133; B + B:187 ± 198;
B + A:41.3 ± 0) were subtracted to the values obtained at days 1, 2, 3, 7 or 14,
respectively for producing a corrected value (Corrected value for cytokine
X = Concentration of cytokine X day n - Concentration of cytokine X day 0).
N.A. not applicable. Symbols (* p= 0.05; } p< 0.05) show days for which
statistical differences were observed between groups of a given experiment
with regards to the proportion of positive pigs. Letters indicate statistically
significant differences for the proportion of responding pigs for similar groups
when comparing between experiments; i.e. naïve pigs inoculated with 3267
(C1 + B) vs. naïve pigs inoculated with 3262 (C2 +A). In this case, a,b
correspond to p≤ 0.1.
Table 8 Serum levels of TGF-β after challenge with PRRSV
at 84 days after the initial inoculation
Corrected† TGF-β levels in serum (pg/mL)
Nº responding pigs; Average ± standard deviation
Experiment 1
Group
Days post-challenge
1 2 3 7 14
C1 + B 0/2 0/2 1/2 1/2 1/2
N.A. N.A. 74 ± N.A. 113 ± N.A. 23 ± 18
A + A 3/4 3/4 4/4 4/4 4/4
50 ± 10 67 ± 17 46 ± 60 93 ± 14 152 ± 110
A + B 3/4 2/4 2/4 4/4a 4/4
57 ± 60 115 ± 60 109 ± 50 99 ± 59 144 ± 90
Experiment 2
Group
Days post-challenge
1 2 3* 7* 14
C2 + A 1/3 1/3 0/3 1/3 1/3
57 ± N.A. 149 ± N.A. N.A. 17 ± N.A. 33 ± N.A.
B + B 4/4 4/4 4/4 4/4 4/4
42 ± 29 42 ± 16 99 ± 41 66 ± 66 109 ± 140
B + A 2/3 2/3 0/3 0/3b 1/3
106 ± 34 109 ± 61 N.A. N.A 37 ± N.A.
† In order to account the pre-2nd challenge levels of a given cytokine, values
(pg/mL) obtained with samples of day 0 (84 pi) (C1 + B:141 ± 20; A + A:58 ± 29;
A + B:86 ± 63; C2 + A:124 ± 107; B + B:137 ± 14; B + A:1036 ± 1701) were
subtracted to the values obtained at days 1, 2, 3, 7 or 14, respectively for
producing a corrected value (Corrected value for cytokine X = Concentration of
cytokine X day n - Concentration of cytokine X day 0).
N.A. not applicable. Symbols (*p ≤ 0.05) show days for which statistical
differences between groups with regards to the proportion of positive pigs
were observed. Letters indicate statistically significant differences for the
proportion of responding pigs for similar groups between experiments; i.e.
naïve pigs inoculated with 3267 (C1 + B) vs. Naïve pigs inoculated with 3262
(C2 + A). In this case, a,b correspond to p ≤ 0.05.
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β from day 1 to 14 post re-inoculation, in the HeC
model TGF-β was detected only sporadically.Discussion
The present study shows that two different PRRSV iso-
lates of genotype I subtype I can produce two different
models of infection based on the clinical, virological and
immunological parameters examined. Although both
models were absent of very overt clinical signs, in one of
them (strain 3262) fever and the decrease in weekly
weight gains were very mild compared to the other
(strain 3267). Differences in the outcome of the inocula-
tion attributable to the breed, genetics, to the origin of
pigs or to different environmental conditions were con-
trolled by using animals from a single farm with a com-
mon genetic and health background. The use of
controlled environment BSL3 facilities reduced variability
attributable to environmental conditions. Regarding the
potential bias caused for concomitant secondary patho-
gens, the results make evident that some pigs in experi-
ment 2 developed a bacterial infection, a fact that wasnot seen in experiment 1. This could have affected the
clinical outcome of the infection after some days of clin-
ical course but is difficult to elucidate the precise impact
of secondary infections on the virological course or on
virus-specific immune responses.
Regarding the virological outcome of the initial chal-
lenge, it was evident that strain 3267 produced longer
and sustained viremias in piglets compared to what
strain 3262 did. Although causes for those different out-
comes cannot be precisely defined at present, those
observations will be coherent with the higher replication
rates of strain 3267 observed in vitro in PAM cultures
compared to those of 3262 (107.0–7.5 versus 105.0–5.9
TCID50/mL after 48 h of incubation at similar m.o.i.,
data not shown). Also, persistence of the virus can have
an individual component as evidenced by the fact that
half of the pigs infected with strain 3267 resolved viremia
by day 42 pi.
For the humoral response, as far as S/P values in
ELISA are concerned, strain 3267 induced higher and
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the nature of this fact is difficult to ascertain with the
available data; it can be hypothesized that the higher sus-
tained replication levels of 3267 could be the cause.
With regards to NA, in the present study it became
evident that their role in clearing viremia during the
course of the infection can be limited. In experiment 1
viremia ceased in absence of detectable NA against the
homologous isolate and in experiment 2, viremia coex-
isted for weeks with NA. Glycosylation of neutralizing
epitopes have been reported to result in a poorer devel-
opment of NA or in increased difficulties for viral
neutralization to occur [27]. Strain 3262 for which devel-
opment of NA did not occur -or could not be demon-
strated- had six potential glycosylation sites in GP3, the
neutralization epitope (NE) in GP4 had a deletion and
the assumed NE in GP5 contained three potential glyco-
sylation sites (N-37, N-46 and N-53). Strain 3267
harbour six potential glycosylation sites in GP3, had an
intact GP4 – very close to that of the reference Lelystad
virus- and harbour two glycosylation sites in GP5 (N-46
and N-53) [15]. Additionally, when the virus 3267
present in blood of viremic pigs at day 49 pi was
sequenced, a third glycosylation site in N-37 of GP5 was
detected and GP4 had suffered some variations in com-
parison with the parental strain (data not shown). Thus
differences in the levels of NA may arise from the differ-
ent characteristics in the sequence and number of glyco-
sylations of the NE of GP3 GP4 and GP5. On the other
hand, when cross-neutralization experiments were per-
formed, it was seen that sera of animals primo-inocu-
lated with strain 3267 were also capable of neutralizing
strain 3262 although with much lower efficiency. Sera
raised against 3262 were devoid of neutralizing capabil-
ities even against the homologous 3262. Considered glo-
bally, these results suggest that in PRRSV, under some
circumstances heterologous NA could be more efficient
than the homologous ones. This has been observed re-
cently by Martínez-Lobo et al. [12]. The nature of this
phenomenon is unknown. Classically, these differences
would have been attributed to changes in the sequence
of the NE and to the number of glycosylations present in
those NE and actually, these changes occurred in the
present study. Nevertheless, in the study by Martínez-
Lobo et al. [12] differences in cross-neutralization in sera
raised against different genotype I strains could not be
related strictly to the sequence and number of glycosyla-
tions of the known GP3, GP4 or GP5 NE and those
authors suggested that maybe the conformational char-
acteristics of the epitopes could have a role on the cross-
reactivity or, alternatively, that other NE unknown yet
exist.
In any case, taking in consideration the abovemen-
tioned facts, if pre-formed NA play a role in protectionagainst PRRSV re-infection as indicated by previous
papers [5,9,27], animals infected/immunised initially by
strain 3262 should be more likely infected upon the HoC
or HeC than animals infected/immunized initially with
3267. This is what occurred and as shown in Tables 4
and 5: animals immunized with strain 3262 developed
viremia after either the HoC or the HeC, although
viremia was of low intensity.
When the cell-mediated compartment of the im-
mune response was examined, it was evident that
strain 3262 induced a stronger virus-specific re-
sponse measured as IFN-γ-SC. Interestingly, this situ-
ation was not reversed by the second challenge at
day 84 pi, even for animals primo-immunized with
3267 and challenged again with 3267. In this case
the higher levels of replication of isolate 3267 did
not seem to contribute to a higher cell-mediated
response.
In a previous study [16] it was shown that infection of
dendritic cells with strain 3267 resulted in an increase of
SLA-II+/CD80/86- and SLA-II-/CD8086+ cells while
strain 3262 induced a decrease in the proportion of
SLA-II+/CD80/86+ cells. Both 3262 and 3267 down regu-
lated SLA-I in infected cells. Also, strains 3267 and 3262
induced different TNF-α and IL-10 responses in den-
dritic cells. These differences may lie behind the different
immune responses developed after the first challenge.
Besides that, strain 3262 produced higher frequencies
of IFN-γ SC when used either as homologous or heterol-
ogous recall stimulus in ELISPOT. This fact points to
the potential differences in the respective capabilities of
the examined strains to inhibit IFN-γ responses or to a
different antigenicity of T-epitopes. Interestingly, after
the second challenge, boost of IFN-γ SC responses were
only seen for pigs showing frequencies lower than 100–
150 cells per million both in experiment 1 and experi-
ment 2, a fact that suggest that this value indicates satur-
ation of the IFN-γ responses. To our knowledge this is
the first report showing differences in cell-mediated
responses against different PRRSV field strains.
When protection against a second challenge was
examined, results showed that weight gains were always
better in the HoC scenario. However, in virological
terms, the picture was different. In experiment 1 (isolate
3262), in which pigs had low or non-detectable levels of
neutralizing antibodies, the outcome of the HoC or HeC
was similar regarding viremia but homologous protec-
tion was better when distribution of virus in tissues was
considered (1/4 positive results in tonsil of pigs in the
HoC versus 4/4 for the HeC).
Since NA against 3262 were not present, or were not
detected, this would indicate that cell-mediated immun-
ity most probably was responsible for limiting the spread
of the infection and the duration of viremia. In
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but NA were higher, viremia was not detected by day 7
post second inoculation. However, that was not truly
sterilizing immunity in all cases as some animals, both in
the HoC and HeC models, harboured PRRSV in tonsils
(but not lungs or spleens). In this second experiment
protection was higher compared to experiment 1 but
some animals did not withstand the challenge even in a
homologous one. In a previous paper it was reported
that protection in the homologous challenge model may
occur with NA titres higher than 1:8 [9]; our results sug-
gest that titres needed for complete protection probably
have to be higher than considered before.
Overall, the results point towards the significance of
each compartment of the immune response in protection
against PRRSV and on the development of future vac-
cines. The results of the present study suggest that pre-
formed NA may have a protective role against infection
but animals devoid of detectable NA may limit the
spread of the infection indicating thus that probably cell-
mediated immunity also contributes to protection.
Regarding the systemic response of cytokines, results
showed that clear differences only occurred for IL-8 and
TGF-β. Although it is difficult to know, we hypothesize
that the reason behind the lack of responses for the
other examined cytokines might be related to the sample
chosen (serum), to the sensitivity of the assay used, but
also it may just reflect the reality. A review of published
paper reveals that a considerable conflict exists measur-
ing IL-10, IL-6 or TNF-α after a PRRSV infection. This
controversy could be due to the different samples or to
the different assay methods used to detect a given cyto-
kine, but also to the viral isolate variability [3]. Similarity
for IL-1, an up-regulation of this cytokine in broncho-al-
veolar lavages have been noticed after a PRRS infection
[28,29], whereas other have observed an up-regulation of
IL-1 in PBMC cultures but no in serum, as in our case,
after the PRRSV infection [30,31]. Regarding IL-8, naïve
animals challenged for first time with 3267 produced
sustained levels of IL-8 for at least one week compared
to the brief responses observed in re-inoculated pigs or
in naïve pigs inoculated with 3262. Those sustained
levels of IL-8 for 3267 strain administered to naïve pigs
are suggestive of a more powerful inflammatory potential
for that strain compared to 3262.
When TGF-β responses were examined in experi-
ment 1, serum levels of this cytokine were observed
mostly in immunized pigs challenged for the second
time but only sporadically in naïve pigs inoculated
anew, suggesting that TGF-β is produced in recall
responses to PRRSV. In the case of pigs previously
immunized with 3267, the HoC produced more sus-
tained levels of serum TGF-β than the HeC perhaps
a suggestion that epitopes involved in the generationof TGF-β producing T-cell clones can be at some ex-
tent dependent on the strain. This would provide an
explanation for previous in vitro observations about
the differential induction of regulatory T-cells by
PRRSV [32].
With the present data, it is clear that almost op-
posite models of immune response to PRRSV could
exist depending on the strain: one based mainly in
the development of NA with low IFN-γ responses,
the other with predominance of IFN-γ responses and
a poor development of NA. Also, the study shows
that in virological terms –but not based on zootech-
nical parameters- heterologous immunity sometimes
could be more efficacious than the homologous one.
This study contributes to emphasize the need for
examining future PRRSV vaccines and PRRS immu-
nopathogenesis studies considering the immunobiolo-
gical diversity of PRRSV strains.
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